Navigation Links
Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement
Date:4/30/2008

- Mikael Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research -

MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as President, Wyeth Research and Senior Vice President, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.

Dr. Ruffolo joined Wyeth in November 2000 and has been responsible for all pharmaceutical research and development (R&D) for the Company, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical R&D and research operations.

"Bob Ruffolo has been the driving force of our R&D progress, establishing Wyeth as one of the research leaders in the pharmaceutical industry," says Bernard Poussot, Wyeth's President and Chief Executive Officer. "His legacy will be our pipeline, recognized as one of the industry's most innovative. Bob has helped position our company for future growth through robust research and development programs in oncology, women's health, vaccines, inflammation, cardiovascular and metabolic diseases and neuroscience -- led by our multi-platform effort in Alzheimer's."

Throughout his 31-year career in the pharmaceutical industry, Dr. Ruffolo's work has been recognized with a number of prestigious awards. In March, he was recognized by the Pharmaceutical Research and Manufacturers of America (PhRMA) with the 2008 Discoverer's Award for his efforts in the discovery and development of Coreg(R) while at GlaxoSmithKline. The Wyeth Research and Development Executive Team (RADEX), formed and chaired by Dr. Ruffolo, won the 2006 Scrip Award for Management Team of the Year. In 2005, he won the George B. Koelle Award for Scientific Excellence. In 2004, he was named Chief Scientific Officer of the Year by IBC Conferences.

Dr. Dohlsten, 49, previously was Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities. Prior to joining Boehringer Ingelheim, Dr. Dohlsten spent more than 15 years in various leadership roles in pharmaceutical research including positions with AstraZeneca and Pharmacia & Upjohn.

Dr. Dohlsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

"We look forward to Dr. Dohlsten's leadership as we work together to continue our success at Wyeth Research," says Bernard Poussot. "His experience with industry in a broad range of therapeutic areas, and his vision going forward, match well with our scientific objectives. We know Mikael's global experience and perspective will be an inspiration to Wyeth's outstanding research teams."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
7. Wyeth Announces Executive Change in Finance Organization
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical ... Office of the National Coordinator for Health IT (ONC) outlining a measurement approach ... data were available when and where it was needed. The organization of health ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling ... her cruciate ligament in her left knee. Lady’s owner Hannah sought the help of ... board-certified veterinary surgeon, to repair her cruciate ligament and help with the pain of ...
(Date:5/24/2016)... AVIV, Israel , May 24, 2016   MedyMatch ... providing physicians with artificial intelligence, real-time decision support tools in ... to present at the 2016 Israeli Advanced Technology Industries (IATI) ... of Israel,s 15th National Life Sciences ... 26th at the David Intercontinental Hotel in Tel ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... The need for blood donations in South ... week by the South Texas Blood & Tissue Center, blood donations are on the decline. ... years, and they are down 21 percent in South Texas in the last four years ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):